NCT03903822 is a Phase 2 clinical trial of PF-06700841 in Atopic Dermatitis, sponsored by Pfizer.

Who is sponsoring NCT03903822?

NCT03903822 is sponsored by Pfizer.

What drugs are being tested in NCT03903822?

Interventions in NCT03903822: PF-06700841, Vehicle (Placebo).

What condition does NCT03903822 study?

NCT03903822 studies Atopic Dermatitis.

Is NCT03903822 still recruiting?

NCT03903822 is currently completed. Last updated 29 March 2021.

Are results published for NCT03903822?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-03-29 · How we verify

NCT03903822

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis

Completed Phase 2 Results posted Last updated 29 March 2021

What this trial tests

Phase 2 trial testing PF-06700841 in Atopic Dermatitis in 292 participants. Completed in 7 May 2020.

Timeline

13 May 2019

Primary endpoint
7 May 2020

7 May 2020

Quick facts

Lead sponsor	Pfizer
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	292
Start date	13 May 2019
Primary completion	7 May 2020
Estimated completion	7 May 2020
Sites	76 locations across Denmark, Japan, Germany, Hungary, Poland, Canada, Bulgaria, Australia

Drugs / interventions tested

PF-06700841 (pf-06700841) — full drug profile →
Vehicle (Placebo)

Conditions studied

Atopic Dermatitis — all drugs for Atopic Dermatitis →

Sponsor

Pfizer — full company profile →

Who can join

Adults 12 to 75, any sex, with Atopic Dermatitis. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 6: Multiple Imputation Primary · Baseline, Week 6

EASI evaluates severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions(head and neck, upper limbs, trunk \[including axillae and groin\] and lower limbs \[including buttocks\]) on4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in each 4 body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	-44.4	-57.3 – -31.6
PF-06700841 0.1% Cream QD	-58.3	-71.2 – -45.5
PF-06700841 0.3% Cream QD	-64.6	-77.1 – -52.1
PF-06700841 1.0% Cream QD	-70.1	-82.1 – -58.0
PF-06700841 3.0% Cream QD	-67.9	-80.6 – -55.3
Vehicle Cream Twice Daily (BID)	-47.6	-57.5 – -37.7
PF-06700841 0.3% Cream BID	-58.6	-67.5 – -49.7
PF-06700841 1.0% Cream BID	-75.0	-83.8 – -66.2

Percentage of Participants Achieving Investigator's Global Assessment (IGA) Score Clear (0) or Almost Clear (1) and a Reduction From Baseline of Greater Than or Equal to ( >=2) Points at Week 6: Non-responder Imputation Secondary · Baseline, Week 6

IGA assesses severity of participant's AD on a 5 point scale. 0= clear, no inflammatory signs of AD; 1= almost clear, AD not fully cleared- light pink residual lesions (except post-inflammatory hyperpigmentation), just perceptible erythema, papulation/induration lichenification, excoriation, and no oozing/crusting; 2= mild AD with light red lesions, slight but definite erythema, papulation/induration, lichenification, excoriation and no oozing/crusting; 3= moderate AD with red lesions, moderate erythema, papulation/induration, lichenification, excoriation and slight oozing/crusting and 4= seve

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	10.8	4.8 – 22.2
PF-06700841 0.1% Cream QD	29.7	18.5 – 43.3
PF-06700841 0.3% Cream QD	33.3	21.3 – 47.0
PF-06700841 1.0% Cream QD	40.5	28.0 – 54.4
PF-06700841 3.0% Cream QD	44.4	30.2 – 59.1
Vehicle Cream Twice Daily (BID)	13.9	6.9 – 25.4
PF-06700841 0.3% Cream BID	33.3	21.3 – 47.0
PF-06700841 1.0% Cream BID	27.0	15.5 – 40.2

Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 6: Multiple Imputation Secondary · Baseline, Week 6

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	-3.2	-4.1 – -2.3
PF-06700841 0.1% Cream QD	-4.5	-5.4 – -3.6
PF-06700841 0.3% Cream QD	-4.6	-5.5 – -3.7
PF-06700841 1.0% Cream QD	-4.8	-5.7 – -3.9
PF-06700841 3.0% Cream QD	-5.5	-6.4 – -4.7
Vehicle Cream Twice Daily (BID)	-3.6	-4.3 – -3.0
PF-06700841 0.3% Cream BID	-4.4	-5.0 – -3.8
PF-06700841 1.0% Cream BID	-5.3	-5.9 – -4.7

Percentage of Participants Achieving >=2 Points Reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Weeks 1, 2, 3, 4 and 6: Non-responder Imputation Secondary · Baseline, Weeks 1, 2, 3, 4 and 6

The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants at specified time points were asked the following question: "How would you rate your itch due to AD at the worst moment during the previous 24 hours?" The scale ranged from 0-10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.

At Week 1

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	16.2	7.3 – 29.3
PF-06700841 0.1% Cream QD	16.7	7.5 – 30.2
PF-06700841 0.3% Cream QD	20.0	11.0 – 33.8
PF-06700841 1.0% Cream QD	29.7	18.5 – 43.3
PF-06700841 3.0% Cream QD	44.4	30.2 – 59.1
Vehicle Cream Twice Daily (BID)	13.9	6.9 – 25.4
PF-06700841 0.3% Cream BID	28.6	16.4 – 41.9
PF-06700841 1.0% Cream BID	25.7	15.4 – 39.2

At Week 2

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	24.3	14.5 – 37.0
PF-06700841 0.1% Cream QD	30.6	18.9 – 44.0
PF-06700841 0.3% Cream QD	42.9	30.0 – 58.1
PF-06700841 1.0% Cream QD	48.6	34.3 – 63.0
PF-06700841 3.0% Cream QD	61.1	47.0 – 74.6
Vehicle Cream Twice Daily (BID)	25.0	14.9 – 38.0
PF-06700841 0.3% Cream BID	45.7	31.7 – 60.8
PF-06700841 1.0% Cream BID	37.1	23.6 – 52.2

At Week 3

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	21.6	11.2 – 34.3
PF-06700841 0.1% Cream QD	38.9	25.4 – 53.0
PF-06700841 0.3% Cream QD	48.6	33.8 – 63.5
PF-06700841 1.0% Cream QD	59.5	45.6 – 72.0
PF-06700841 3.0% Cream QD	58.3	44.0 – 71.0
Vehicle Cream Twice Daily (BID)	33.3	21.3 – 47.0
PF-06700841 0.3% Cream BID	51.4	36.5 – 66.2
PF-06700841 1.0% Cream BID	57.1	41.9 – 70.0

At Week 4

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	35.1	22.2 – 49.3
PF-06700841 0.1% Cream QD	38.9	25.4 – 53.0
PF-06700841 0.3% Cream QD	51.4	36.5 – 66.2
PF-06700841 1.0% Cream QD	62.2	48.0 – 75.2
PF-06700841 3.0% Cream QD	58.3	44.0 – 71.0
Vehicle Cream Twice Daily (BID)	30.6	18.9 – 44.0
PF-06700841 0.3% Cream BID	60.0	44.8 – 74.0
PF-06700841 1.0% Cream BID	60.0	44.8 – 74.0

At Week 6

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	40.5	28.0 – 54.4
PF-06700841 0.1% Cream QD	41.7	29.0 – 56.0
PF-06700841 0.3% Cream QD	51.4	36.5 – 66.2
PF-06700841 1.0% Cream QD	56.8	43.2 – 70.7
PF-06700841 3.0% Cream QD	61.1	47.0 – 74.6
Vehicle Cream Twice Daily (BID)	30.6	18.9 – 44.0
PF-06700841 0.3% Cream BID	60.0	44.8 – 74.0
PF-06700841 1.0% Cream BID	60.0	44.8 – 74.0

Percentage of Participants Achieving >=4 Points Reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Weeks 1, 2, 3, 4, 6 and Follow-up Visit: Non-responder Imputation Secondary · Baseline, Weeks 1, 2, 3, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)

At Week 1

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	0.0	0.0 – 8.2
PF-06700841 0.1% Cream QD	3.3	0.4 – 14.0
PF-06700841 0.3% Cream QD	3.1	0.3 – 13.1
PF-06700841 1.0% Cream QD	16.1	8.1 – 29.7
PF-06700841 3.0% Cream QD	10.7	4.0 – 23.8
Vehicle Cream Twice Daily (BID)	3.3	0.4 – 14.0
PF-06700841 0.3% Cream BID	3.3	0.4 – 14.0
PF-06700841 1.0% Cream BID	11.1	4.2 – 24.8

At Week 2

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	9.1	3.4 – 20.2
PF-06700841 0.1% Cream QD	10.0	3.7 – 22.1
PF-06700841 0.3% Cream QD	9.4	3.5 – 20.7
PF-06700841 1.0% Cream QD	19.4	8.8 – 32.7
PF-06700841 3.0% Cream QD	25.0	13.9 – 40.0
Vehicle Cream Twice Daily (BID)	10.0	3.7 – 22.1
PF-06700841 0.3% Cream BID	13.3	5.9 – 27.9
PF-06700841 1.0% Cream BID	33.3	20.4 – 50.0

At Week 3

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	12.1	5.4 – 25.1
PF-06700841 0.1% Cream QD	23.3	12.9 – 37.6
PF-06700841 0.3% Cream QD	15.6	7.8 – 28.7
PF-06700841 1.0% Cream QD	32.3	18.7 – 48.2
PF-06700841 3.0% Cream QD	32.1	19.7 – 47.3
Vehicle Cream Twice Daily (BID)	10.0	3.7 – 22.1
PF-06700841 0.3% Cream BID	20.0	9.1 – 33.9
PF-06700841 1.0% Cream BID	37.0	22.1 – 54.7

At Week 4

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	18.2	8.2 – 31.3
PF-06700841 0.1% Cream QD	26.7	14.0 – 41.6
PF-06700841 0.3% Cream QD	28.1	17.0 – 43.3
PF-06700841 1.0% Cream QD	35.5	21.3 – 51.8
PF-06700841 3.0% Cream QD	50.0	33.3 – 66.7
Vehicle Cream Twice Daily (BID)	10.0	3.7 – 22.1
PF-06700841 0.3% Cream BID	30.0	18.2 – 45.5
PF-06700841 1.0% Cream BID	37.0	22.1 – 54.7

At Week 6

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	18.2	8.2 – 31.3
PF-06700841 0.1% Cream QD	30.0	18.2 – 45.5
PF-06700841 0.3% Cream QD	34.4	20.7 – 50.0
PF-06700841 1.0% Cream QD	45.2	29.7 – 60.1
PF-06700841 3.0% Cream QD	50.0	33.3 – 66.7
Vehicle Cream Twice Daily (BID)	16.7	8.3 – 30.8
PF-06700841 0.3% Cream BID	33.3	19.3 – 49.2
PF-06700841 1.0% Cream BID	40.7	24.8 – 58.3

At Follow-up visit

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	9.1	3.4 – 20.2
PF-06700841 0.1% Cream QD	30.0	18.2 – 45.5
PF-06700841 0.3% Cream QD	21.9	12.1 – 36.2
PF-06700841 1.0% Cream QD	19.4	8.8 – 32.7
PF-06700841 3.0% Cream QD	21.4	9.8 – 36.6
Vehicle Cream Twice Daily (BID)	20.0	9.1 – 33.9
PF-06700841 0.3% Cream BID	20.0	9.1 – 33.9
PF-06700841 1.0% Cream BID	7.4	2.0 – 20.4

Percent Change From Baseline in Affected Body Surface Area (BSA) at Weeks 1, 2, 3, 4, 6 and Follow-up Visit Secondary · Baseline, Weeks 1, 2, 3, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)

4 body regions were evaluated: head and neck, upper limbs, trunk (including axillae and groin) and lower limbs (including buttocks). Scalp, palms and soles were excluded. BSA was calculated using handprint method. Number of handprints (size of participant's full palmer hand) fitting in the affected area of a body region was estimated. Maximum number of handprints were 10 for head and neck, 20 for upper limbs, 30 for trunk and 40 for lower limbs. Surface area of body region equivalent to 1 handprint: 1 handprint was equal to 10% for head and neck, 5% for upper limbs, 3.33% for trunk and 2.5% fo

At Week 1

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	-2.4	-12.2 – 7.4
PF-06700841 0.1% Cream QD	-2.9	-12.5 – 6.8
PF-06700841 0.3% Cream QD	-16.2	-26.2 – -6.2
PF-06700841 1.0% Cream QD	-19.9	-29.6 – -10.2
PF-06700841 3.0% Cream QD	-23.0	-32.8 – -13.1
Vehicle Cream Twice Daily (BID)	8.5	-8.3 – 25.3
PF-06700841 0.3% Cream BID	-16.5	-32.9 – -0.1
PF-06700841 1.0% Cream BID	-17.0	-33.5 – -0.5

At Week 2

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	-15.3	-28.0 – -2.6
PF-06700841 0.1% Cream QD	-7.2	-20.2 – 5.8
PF-06700841 0.3% Cream QD	-38.1	-51.0 – -25.2
PF-06700841 1.0% Cream QD	-43.6	-56.5 – -30.8
PF-06700841 3.0% Cream QD	-39.0	-52.1 – -26.0
Vehicle Cream Twice Daily (BID)	-2.5	-14.0 – 9.1
PF-06700841 0.3% Cream BID	-34.2	-45.4 – -22.9
PF-06700841 1.0% Cream BID	-43.1	-54.5 – -31.6

At Week 3

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	-17.1	-31.0 – -3.1
PF-06700841 0.1% Cream QD	-13.1	-27.4 – 1.1
PF-06700841 0.3% Cream QD	-50.6	-64.4 – -36.7
PF-06700841 1.0% Cream QD	-55.9	-69.7 – -42.0
PF-06700841 3.0% Cream QD	-49.2	-63.2 – -35.1
Vehicle Cream Twice Daily (BID)	-25.2	-39.2 – -11.1
PF-06700841 0.3% Cream BID	-39.8	-53.0 – -26.6
PF-06700841 1.0% Cream BID	-44.0	-57.1 – -30.9

At Week 4

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	-25.9	-39.8 – -12.0
PF-06700841 0.1% Cream QD	-20.1	-34.4 – -5.7
PF-06700841 0.3% Cream QD	-55.8	-69.5 – -42.1
PF-06700841 1.0% Cream QD	-57.9	-71.7 – -44.0
PF-06700841 3.0% Cream QD	-56.7	-70.8 – -42.7
Vehicle Cream Twice Daily (BID)	-34.7	-46.1 – -23.3
PF-06700841 0.3% Cream BID	-46.4	-56.9 – -35.9
PF-06700841 1.0% Cream BID	-57.7	-68.2 – -47.2

At Week 6

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	-21.6	-38.0 – -5.3
PF-06700841 0.1% Cream QD	-39.4	-56.1 – -22.7
PF-06700841 0.3% Cream QD	-59.4	-75.4 – -43.5
PF-06700841 1.0% Cream QD	-63.6	-79.5 – -47.6
PF-06700841 3.0% Cream QD	-60.3	-76.4 – -44.1
Vehicle Cream Twice Daily (BID)	-31.2	-42.5 – -20.0
PF-06700841 0.3% Cream BID	-48.9	-59.3 – -38.6
PF-06700841 1.0% Cream BID	-65.0	-75.3 – -54.7

At Follow-up visit

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	-23.6	-39.5 – -7.6
PF-06700841 0.1% Cream QD	-24.5	-41.0 – -8.0
PF-06700841 0.3% Cream QD	-42.7	-58.1 – -27.2
PF-06700841 1.0% Cream QD	-37.0	-52.6 – -21.4
PF-06700841 3.0% Cream QD	-55.2	-71.8 – -38.6
Vehicle Cream Twice Daily (BID)	-26.3	-47.5 – -5.2
PF-06700841 0.3% Cream BID	-31.6	-52.0 – -11.3
PF-06700841 1.0% Cream BID	-24.6	-45.2 – -4.1

Percentage of Participants Achieving >=75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline at Weeks 1, 2, 3, 4 and 6: Non-responder Imputation Secondary · Baseline, Weeks 1, 2, 3, 4 and 6

At Week 1

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	5.4	1.4 – 15.5
PF-06700841 0.1% Cream QD	0.0	0.0 – 7.3
PF-06700841 0.3% Cream QD	19.4	10.7 – 32.8
PF-06700841 1.0% Cream QD	5.4	1.4 – 15.5
PF-06700841 3.0% Cream QD	16.7	7.5 – 30.2
Vehicle Cream Twice Daily (BID)	0.0	0.0 – 7.5
PF-06700841 0.3% Cream BID	13.9	6.9 – 25.4
PF-06700841 1.0% Cream BID	21.6	11.2 – 34.3

At Week 2

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	8.1	3.0 – 18.5
PF-06700841 0.1% Cream QD	10.8	4.8 – 22.2
PF-06700841 0.3% Cream QD	27.8	15.9 – 40.9
PF-06700841 1.0% Cream QD	24.3	14.5 – 37.0
PF-06700841 3.0% Cream QD	38.9	25.4 – 53.0
Vehicle Cream Twice Daily (BID)	13.9	6.9 – 25.4
PF-06700841 0.3% Cream BID	25.0	14.9 – 38.0
PF-06700841 1.0% Cream BID	32.4	20.6 – 46.4

At Week 3

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	5.4	1.4 – 15.5
PF-06700841 0.1% Cream QD	16.2	7.3 – 29.3
PF-06700841 0.3% Cream QD	36.1	22.9 – 50.0
PF-06700841 1.0% Cream QD	43.2	29.3 – 56.8
PF-06700841 3.0% Cream QD	41.7	29.0 – 56.0
Vehicle Cream Twice Daily (BID)	19.4	10.7 – 32.8
PF-06700841 0.3% Cream BID	19.4	10.7 – 32.8
PF-06700841 1.0% Cream BID	43.2	29.3 – 56.8

At Week 4

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	24.3	14.5 – 37.0
PF-06700841 0.1% Cream QD	21.6	11.2 – 34.3
PF-06700841 0.3% Cream QD	38.9	25.4 – 53.0
PF-06700841 1.0% Cream QD	43.2	29.3 – 56.8
PF-06700841 3.0% Cream QD	50.0	35.3 – 64.7
Vehicle Cream Twice Daily (BID)	22.2	11.6 – 35.3
PF-06700841 0.3% Cream BID	36.1	22.9 – 50.0
PF-06700841 1.0% Cream BID	48.6	34.3 – 63.0

At Week 6

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	35.1	22.2 – 49.3
PF-06700841 0.1% Cream QD	32.4	20.6 – 46.4
PF-06700841 0.3% Cream QD	52.8	38.0 – 67.2
PF-06700841 1.0% Cream QD	54.1	40.2 – 68.2
PF-06700841 3.0% Cream QD	50.0	35.3 – 64.7
Vehicle Cream Twice Daily (BID)	16.7	7.5 – 30.2
PF-06700841 0.3% Cream BID	36.1	22.9 – 50.0
PF-06700841 1.0% Cream BID	51.4	37.0 – 65.7

Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) Secondary · Baseline (Day 1) up to at least 28 days after last dose of study drug (approximately up to Week 11)

An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. Treatment-emergent were events between first dose of investigational product and up to 28 days after the last dose of investigational product

TEAEs

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	18
PF-06700841 0.1% Cream QD	17
PF-06700841 0.3% Cream QD	11
PF-06700841 1.0% Cream QD	12
PF-06700841 3.0% Cream QD	10
Vehicle Cream Twice Daily (BID)	17
PF-06700841 0.3% Cream BID	9
PF-06700841 1.0% Cream BID	14

SAEs

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	0
PF-06700841 0.1% Cream QD	0
PF-06700841 0.3% Cream QD	0
PF-06700841 1.0% Cream QD	0
PF-06700841 3.0% Cream QD	0
Vehicle Cream Twice Daily (BID)	0
PF-06700841 0.3% Cream BID	0
PF-06700841 1.0% Cream BID	0

Number of Participants With Pre-defined Criteria For Vital Signs Secondary · Baseline up to Week 6

Pre-defined criteria included: 1) Diastolic blood pressure (DBP), a) sitting DBP: change of \>= 20 millimeter of mercury (mmHg) increase, b) sitting DBP: change of \>=20mmHg decrease, c) supine DBP: less than (\<) 50 mmHg, d) supine DBP: change of \>= 20mmHg increase, e) supine DBP: change of \>= 20mmHg decrease; 2) Systolic blood pressure (SBP), a) sitting SBP: \<90 mmHg, b) sitting SBP: change of \>=30mmHg increase, c) sitting SBP: change of \>=30mmHg decrease, d) supine SBP: change of \>=30mmHg increase, e) supine SBP: change of \>=30mmHg decrease and f) Supine SBP: value \<90mmHg.

Sitting DBP: Change >= 20 mm Hg increase

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	0
PF-06700841 0.1% Cream QD	0
PF-06700841 0.3% Cream QD	1
PF-06700841 1.0% Cream QD	2
PF-06700841 3.0% Cream QD	0
Vehicle Cream Twice Daily (BID)	0
PF-06700841 0.3% Cream BID	0
PF-06700841 1.0% Cream BID	0

Sitting DBP: Change >= 20mmHg decrease

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	1
PF-06700841 0.1% Cream QD	0
PF-06700841 0.3% Cream QD	0
PF-06700841 1.0% Cream QD	1
PF-06700841 3.0% Cream QD	0
Vehicle Cream Twice Daily (BID)	1
PF-06700841 0.3% Cream BID	0
PF-06700841 1.0% Cream BID	0

Supine DBP: Value <50 mmHg

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	0
PF-06700841 0.1% Cream QD	0
PF-06700841 0.3% Cream QD	0
PF-06700841 1.0% Cream QD	0
PF-06700841 3.0% Cream QD	0
Vehicle Cream Twice Daily (BID)	1
PF-06700841 0.3% Cream BID	0
PF-06700841 1.0% Cream BID	0

Supine DBP: Change >= 20mmHg increase

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	0
PF-06700841 0.1% Cream QD	1
PF-06700841 0.3% Cream QD	1
PF-06700841 1.0% Cream QD	2
PF-06700841 3.0% Cream QD	1
Vehicle Cream Twice Daily (BID)	0
PF-06700841 0.3% Cream BID	1
PF-06700841 1.0% Cream BID	0

Supine DBP: Change >= 20mmHg decrease

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	0
PF-06700841 0.1% Cream QD	0
PF-06700841 0.3% Cream QD	0
PF-06700841 1.0% Cream QD	0
PF-06700841 3.0% Cream QD	0
Vehicle Cream Twice Daily (BID)	0
PF-06700841 0.3% Cream BID	1
PF-06700841 1.0% Cream BID	0

Sitting SBP: <90mmHg

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	0
PF-06700841 0.1% Cream QD	0
PF-06700841 0.3% Cream QD	0
PF-06700841 1.0% Cream QD	1
PF-06700841 3.0% Cream QD	0
Vehicle Cream Twice Daily (BID)	0
PF-06700841 0.3% Cream BID	0
PF-06700841 1.0% Cream BID	0

Sitting SBP: change >= 30mmHg increase

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	0
PF-06700841 0.1% Cream QD	0
PF-06700841 0.3% Cream QD	0
PF-06700841 1.0% Cream QD	1
PF-06700841 3.0% Cream QD	0
Vehicle Cream Twice Daily (BID)	0
PF-06700841 0.3% Cream BID	0
PF-06700841 1.0% Cream BID	1

Sitting SBP: change >= 30mmHg decrease

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	0
PF-06700841 0.1% Cream QD	0
PF-06700841 0.3% Cream QD	0
PF-06700841 1.0% Cream QD	0
PF-06700841 3.0% Cream QD	1
Vehicle Cream Twice Daily (BID)	0
PF-06700841 0.3% Cream BID	0
PF-06700841 1.0% Cream BID	0

Number of Participants With Laboratory Abnormalities Secondary · Baseline (Day 1) up to at least 28 days after last dose of study drug (approximately up to Week 11)

Hemoglobin (HGB),hematocrit,erythrocytes (ery.),HDL cholesterol (chl.)\<0.8\*lower limit of normal(LLN);reticulocytes (ret.), ret./ery. (%)\<0.5\*LLN,\>1.5\*upper limit of normal (ULN);ery. mean corpuscular (EMC) volume,EMC HGB,EMC HGB concentration,potassium,chloride,calcium,bicarbonate\<0.9\*LLN,\>1.1\*ULN;platelets\<0.5\*LLN,\>1.75\*ULN;leukocytes (leu.),glucose\<0.6\*LLN,\>1.5\*ULN;lymphocytes (lym.), lym./leu.(%), neutrophils (neu.), neu./leu. (%), protein,albumin \<0.8\*LLN,\>1.2\*ULN;basophils (bas.), bas./leu.(%), eosinophils (eos.), eos./leu., monocytes (mon.), mon./leu.(%), urate \>1

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	26
PF-06700841 0.1% Cream QD	22
PF-06700841 0.3% Cream QD	23
PF-06700841 1.0% Cream QD	22
PF-06700841 3.0% Cream QD	16
Vehicle Cream Twice Daily (BID)	21
PF-06700841 0.3% Cream BID	24
PF-06700841 1.0% Cream BID	24

Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Findings Secondary · Baseline up to Week 6

Clinically significant ECG criteria included PR interval: value greater than (\>) 280 millisecond (msec), percentage change greater than equal to (\>=) 25/50 percentage, QRS interval: value \>120 msec, percentage change \>= 50% and QT interval corrected using the Fridericia's formula (QTCF) value 450 msec and 30\<=change\<60.

PR interval : value >280 msec

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	0
PF-06700841 0.1% Cream QD	0
PF-06700841 0.3% Cream QD	0
PF-06700841 1.0% Cream QD	0
PF-06700841 3.0% Cream QD	1
Vehicle Cream Twice Daily (BID)	0
PF-06700841 0.3% Cream BID	0
PF-06700841 1.0% Cream BID	0

PR interval : %change>=25/50%

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	0
PF-06700841 0.1% Cream QD	1
PF-06700841 0.3% Cream QD	1
PF-06700841 1.0% Cream QD	0
PF-06700841 3.0% Cream QD	1
Vehicle Cream Twice Daily (BID)	0
PF-06700841 0.3% Cream BID	2
PF-06700841 1.0% Cream BID	0

QRS interval: value >120 msec

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	0
PF-06700841 0.1% Cream QD	0
PF-06700841 0.3% Cream QD	0
PF-06700841 1.0% Cream QD	0
PF-06700841 3.0% Cream QD	0
Vehicle Cream Twice Daily (BID)	0
PF-06700841 0.3% Cream BID	1
PF-06700841 1.0% Cream BID	1

QRS interval: %Change>=50%

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	0
PF-06700841 0.1% Cream QD	0
PF-06700841 0.3% Cream QD	0
PF-06700841 1.0% Cream QD	0
PF-06700841 3.0% Cream QD	0
Vehicle Cream Twice Daily (BID)	1
PF-06700841 0.3% Cream BID	0
PF-06700841 1.0% Cream BID	0

QTCF: 450 msec

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	0
PF-06700841 0.1% Cream QD	0
PF-06700841 0.3% Cream QD	1
PF-06700841 1.0% Cream QD	1
PF-06700841 3.0% Cream QD	0
Vehicle Cream Twice Daily (BID)	1
PF-06700841 0.3% Cream BID	0
PF-06700841 1.0% Cream BID	0

QTCF: 30<=Change<60

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	0
PF-06700841 0.1% Cream QD	1
PF-06700841 0.3% Cream QD	1
PF-06700841 1.0% Cream QD	1
PF-06700841 3.0% Cream QD	1
Vehicle Cream Twice Daily (BID)	2
PF-06700841 0.3% Cream BID	1
PF-06700841 1.0% Cream BID	0

Change From Baseline in Clinical Chemistry-Lactate Dehydrogenase Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit Secondary · Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)

Change at week 1

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	0.4	± 25.99
PF-06700841 0.1% Cream QD	-7.4	± 30.20
PF-06700841 0.3% Cream QD	-5.3	± 16.99
PF-06700841 1.0% Cream QD	-9.3	± 22.65
PF-06700841 3.0% Cream QD	-18.4	± 33.42
Vehicle Cream Twice Daily (BID)	-8.0	± 34.51
PF-06700841 0.3% Cream BID	-8.0	± 19.37
PF-06700841 1.0% Cream BID	-4.3	± 29.08

Change at week 2

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	-8.8	± 21.56
PF-06700841 0.1% Cream QD	-7.8	± 27.99
PF-06700841 0.3% Cream QD	-1.9	± 18.18
PF-06700841 1.0% Cream QD	-8.8	± 23.70
PF-06700841 3.0% Cream QD	-15.8	± 42.19
Vehicle Cream Twice Daily (BID)	-0.3	± 22.81
PF-06700841 0.3% Cream BID	-8.0	± 22.31
PF-06700841 1.0% Cream BID	-4.9	± 24.49

Change at week 4

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	-8.6	± 23.93
PF-06700841 0.1% Cream QD	-5.4	± 22.87
PF-06700841 0.3% Cream QD	-9.3	± 19.61
PF-06700841 1.0% Cream QD	-12.1	± 28.54
PF-06700841 3.0% Cream QD	-16.3	± 33.97
Vehicle Cream Twice Daily (BID)	-1.0	± 29.29
PF-06700841 0.3% Cream BID	-19.5	± 19.94
PF-06700841 1.0% Cream BID	-3.7	± 24.96

Change at week 6

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	-8.8	± 18.25
PF-06700841 0.1% Cream QD	-8.1	± 32.02
PF-06700841 0.3% Cream QD	-1.5	± 32.42
PF-06700841 1.0% Cream QD	-6.4	± 28.53
PF-06700841 3.0% Cream QD	-18.2	± 33.86
Vehicle Cream Twice Daily (BID)	-9.7	± 20.68
PF-06700841 0.3% Cream BID	-11.2	± 22.34
PF-06700841 1.0% Cream BID	-7.0	± 24.65

Change at follow-up visit

Group	Value	95% CI
Vehicle Cream Once Daily (QD)	-12.3	± 24.82
PF-06700841 0.1% Cream QD	-12.0	± 28.83
PF-06700841 0.3% Cream QD	4.0	± 43.45
PF-06700841 1.0% Cream QD	-2.7	± 26.27
PF-06700841 3.0% Cream QD	-15.1	± 38.23
Vehicle Cream Twice Daily (BID)	-11.3	± 29.39
PF-06700841 0.3% Cream BID	-13.3	± 25.37
PF-06700841 1.0% Cream BID	0.2	± 16.48

Adverse events — posted to ClinicalTrials.gov

Time frame: Baseline (Day 1) up to at least 28 days after last dose of study drug (approximately up to Week 11). Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Vehicle Cream Once Daily (QD)

Serious: 0/37 (0%)

Deaths: 0/37

PF-06700841 0.1% Cream QD

Serious: 0/37 (0%)

Deaths: 0/37

PF-06700841 0.3% Cream QD

Serious: 0/36 (0%)

Deaths: 0/36

PF-06700841 1.0% Cream QD

Serious: 0/37 (0%)

Deaths: 0/37

PF-06700841 3.0% Cream QD

Serious: 0/36 (0%)

Deaths: 0/36

Vehicle Cream Twice Daily (BID)

Serious: 0/36 (0%)

Deaths: 0/36

PF-06700841 0.3% Cream BID

Serious: 0/36 (0%)

Deaths: 0/36

PF-06700841 1.0% Cream BID

Serious: 0/37 (0%)

Deaths: 0/37

Other adverse events (86 terms — click to expand)

Reaction	System	Vehicle Cream Once Daily (…	PF-06700841 0.1% Cream QD	PF-06700841 0.3% Cream QD	PF-06700841 1.0% Cream QD	PF-06700841 3.0% Cream QD	Vehicle Cream Twice Daily …	PF-06700841 0.3% Cream BID	PF-06700841 1.0% Cream BID
Nasopharyngitis	Infections and infestations	—	—	—	—	—	—	—	—
Application site pruritus	General disorders	—	—	—	—	—	—	—	—
Dermatitis atopic	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—
Application site erythema	General disorders	—	—	—	—	—	—	—	—
Influenza	Infections and infestations	—	—	—	—	—	—	—	—
Urinary tract infection	Infections and infestations	—	—	—	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—
Oropharyngeal pain	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—
Pruritus	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—
Swelling of eyelid	Eye disorders	—	—	—	—	—	—	—	—
Ulcerative keratitis	Eye disorders	—	—	—	—	—	—	—	—
Dyspepsia	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Administration site warmth	General disorders	—	—	—	—	—	—	—	—
Application site acne	General disorders	—	—	—	—	—	—	—	—
Application site pain	General disorders	—	—	—	—	—	—	—	—
Chills	General disorders	—	—	—	—	—	—	—	—
Injection site pain	General disorders	—	—	—	—	—	—	—	—
Oedema peripheral	General disorders	—	—	—	—	—	—	—	—
Pain	General disorders	—	—	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—	—	—
Vessel puncture site haematoma	General disorders	—	—	—	—	—	—	—	—
Allergy to arthropod sting	Immune system disorders	—	—	—	—	—	—	—	—
Cockroach allergy	Immune system disorders	—	—	—	—	—	—	—	—
Mite allergy	Immune system disorders	—	—	—	—	—	—	—	—
Bacterial allergy	Infections and infestations	—	—	—	—	—	—	—	—
Bronchitis	Infections and infestations	—	—	—	—	—	—	—	—
Conjunctivitis	Infections and infestations	—	—	—	—	—	—	—	—
Cystitis	Infections and infestations	—	—	—	—	—	—	—	—
Eczema infected	Infections and infestations	—	—	—	—	—	—	—	—
Folliculitis	Infections and infestations	—	—	—	—	—	—	—	—
Furuncle	Infections and infestations	—	—	—	—	—	—	—	—
Gastroenteritis	Infections and infestations	—	—	—	—	—	—	—	—
Gastroenteritis viral	Infections and infestations	—	—	—	—	—	—	—	—
Gingivitis	Infections and infestations	—	—	—	—	—	—	—	—
Herpes simplex	Infections and infestations	—	—	—	—	—	—	—	—
Kaposi's varicelliform eruption	Infections and infestations	—	—	—	—	—	—	—	—
Laryngitis	Infections and infestations	—	—	—	—	—	—	—	—
Oral herpes	Infections and infestations	—	—	—	—	—	—	—	—
Pharyngitis	Infections and infestations	—	—	—	—	—	—	—	—

Data from ClinicalTrials.gov NCT03903822 adverse events section.

Sponsor's own description

This study is being conducted to provide data on efficacy, safety, tolerability and PK of multiple topical formulation concentrations of PF-06700841 topical cream in the treatment of mild to moderate atopic dermatitis (AD). The study is intended to enable selection of the dose and dosing regimen (once daily \[QD\] vs twice daily \[BID\] application) for the future clinical development of topical PF-06700841.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Atopic dermatitis: an expanding therapeutic pipeline for a complex disease.
Bieber T. · · 2022 · cited 421× · PMID 34417579 · DOI 10.1038/s41573-021-00266-6
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach.
Tanaka Y, Luo Y, O'Shea JJ, Nakayamada S. · · 2022 · cited 329× · PMID 34987201 · DOI 10.1038/s41584-021-00726-8
JAK inhibitors in the treatment of atopic dermatitis.
Chovatiya R, Paller AS. · · 2021 · cited 258× · PMID 34437922 · DOI 10.1016/j.jaci.2021.08.009
JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review.
Huang IH, Chung WH, Wu PC, Chen CB. · · 2022 · cited 195× · PMID 36569854 · DOI 10.3389/fimmu.2022.1068260
Targeting the Janus Kinase Family in Autoimmune Skin Diseases.
Howell MD, Kuo FI, Smith PA. · · 2019 · cited 180× · PMID 31649667 · DOI 10.3389/fimmu.2019.02342
Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story.
Bonelli M, Kerschbaumer A, Kastrati K, Ghoreschi K, et al · · 2024 · cited 95× · PMID 37923366 · DOI 10.1136/ard-2023-223850
Mendelian randomization and clinical trial evidence supports TYK2 inhibition as a therapeutic target for autoimmune diseases.
Yuan S, Wang L, Zhang H, Xu F, et al · · 2023 · cited 61× · PMID 36842216 · DOI 10.1016/j.ebiom.2023.104488
Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors.
Jensen LT, Attfield KE, Feldmann M, Fugger L. · · 2023 · cited 45× · PMID 37863021 · DOI 10.1016/j.ebiom.2023.104840

Verify or expand the search:

Other trials of PF-06700841

Trials testing the same drug.

NCT05076006 — Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia · Phase 2 · completed
NCT04267250 — Effect Of Multiple Dose PF-06700841 On The Pharmacokinetics Of Single Dose Oral Contraceptive Steroids · Phase 1 · completed
NCT04260464 — Renal Impairment Study of PF-06700841 · Phase 1 · completed
NCT04092452 — A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Sup · Phase 2 · completed
NCT04090047 — A Study to Investigate the Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of PF-06700841 in Healthy Pa · Phase 1 · completed

Other recruiting trials for Atopic Dermatitis

Currently open trials in the same condition.

NCT07262983 — Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopi · Phase 1 · recruiting
NCT07445919 — A Clinical Study to Evaluate SM17 for Atopic Dermatitis · Phase 2 · recruiting
NCT07488065 — A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants · Phase 1 · recruiting
NCT07467564 — The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatit · recruiting
NCT07358156 — A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and E · Phase 1 · recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03903822 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 29 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03903822.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT03903822

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Sponsor's own description

Publications & conference data

Related trials

Other trials of PF-06700841

Other recruiting trials for Atopic Dermatitis

Other Pfizer trials

Verify against primary sources